Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
accepted:
19
08
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
8
10
2024
Statut:
aheadofprint
Résumé
The phase III KEYNOTE-913 study was conducted to evaluate the efficacy and safety of pembrolizumab as first-line therapy in patients with advanced Merkel cell carcinoma (MCC). The aim was to report results from the primary analysis of KEYNOTE-913. Patients with recurrent locally advanced or metastatic MCC received pembrolizumab 200 mg intravenously every 3 weeks for up to 35 treatments (~ 2 years). The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central review (BICR). Secondary end points were duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1 by BICR, overall survival (OS), and safety and tolerability. Fifty-five patients were treated with pembrolizumab. The median time from first dose to data cutoff (February 15, 2024) was 50.3 months (range 38.7-59.4). The ORR was 49% (95% confidence interval [CI] 35-63), with 12 complete responses and 15 partial responses. The median DOR was 39.8 months (range 4.8-52.5+), and the 24-month DOR rate was 69%. The median PFS was 9.3 months (95% CI 3-26), and the 24-month PFS rate was 39%. The median OS was 24.3 months (95% CI 12.4 to not reached), and the 24-month OS rate was 51%. Any-grade treatment-related adverse events (AEs) occurred in 38 patients (69%); 13 patients (24%) experienced grade 3-5 AEs. The most common treatment-related AEs were fatigue (n = 12 [22%]), pruritus (n = 12 [22%]), and lipase increase (n = 10 [18%]). One patient died of treatment-related Guillain-Barré syndrome. Pembrolizumab provided durable antitumor activity and promising survival and had a manageable safety profile in patients with recurrent locally advanced or metastatic MCC, supporting its use in this population. Clinicaltrials.gov, NCT03783078.
Sections du résumé
BACKGROUND
BACKGROUND
The phase III KEYNOTE-913 study was conducted to evaluate the efficacy and safety of pembrolizumab as first-line therapy in patients with advanced Merkel cell carcinoma (MCC).
OBJECTIVE
OBJECTIVE
The aim was to report results from the primary analysis of KEYNOTE-913.
PATIENTS AND METHODS
METHODS
Patients with recurrent locally advanced or metastatic MCC received pembrolizumab 200 mg intravenously every 3 weeks for up to 35 treatments (~ 2 years). The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central review (BICR). Secondary end points were duration of response (DOR) and progression-free survival (PFS) per RECIST v1.1 by BICR, overall survival (OS), and safety and tolerability.
RESULTS
RESULTS
Fifty-five patients were treated with pembrolizumab. The median time from first dose to data cutoff (February 15, 2024) was 50.3 months (range 38.7-59.4). The ORR was 49% (95% confidence interval [CI] 35-63), with 12 complete responses and 15 partial responses. The median DOR was 39.8 months (range 4.8-52.5+), and the 24-month DOR rate was 69%. The median PFS was 9.3 months (95% CI 3-26), and the 24-month PFS rate was 39%. The median OS was 24.3 months (95% CI 12.4 to not reached), and the 24-month OS rate was 51%. Any-grade treatment-related adverse events (AEs) occurred in 38 patients (69%); 13 patients (24%) experienced grade 3-5 AEs. The most common treatment-related AEs were fatigue (n = 12 [22%]), pruritus (n = 12 [22%]), and lipase increase (n = 10 [18%]). One patient died of treatment-related Guillain-Barré syndrome.
CONCLUSIONS
CONCLUSIONS
Pembrolizumab provided durable antitumor activity and promising survival and had a manageable safety profile in patients with recurrent locally advanced or metastatic MCC, supporting its use in this population.
TRIAL REGISTRATION
BACKGROUND
Clinicaltrials.gov, NCT03783078.
Identifiants
pubmed: 39377880
doi: 10.1007/s40257-024-00885-w
pii: 10.1007/s40257-024-00885-w
doi:
Banques de données
ClinicalTrials.gov
['NCT03783078']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mcevoy AM, Lachance K, Hippe DS, Cahill K, Moshiri Y, Lewis CW, et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382–9.
doi: 10.1001/jamadermatol.2021.6096
pubmed: 35195657
pmcid: 8867389
Lewis CW, Qazi J, Hippe DS, Lachance K, Thomas H, Cook MM, et al. Patterns of distant metastases in 215 Merkel cell carcinoma patients: implications for prognosis and surveillance. Cancer Med. 2020;9(4):1374–82.
doi: 10.1002/cam4.2781
pubmed: 31883234
Harms KL, Healy MA, Nghiem P, Sober AJ, Johnson TM, Bichakjian CK, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23(11):3564–71.
doi: 10.1245/s10434-016-5266-4
pubmed: 27198511
pmcid: 8881989
DeCaprio JA. Molecular pathogenesis of Merkel cell carcinoma. Annu Rev Pathol. 2021;16:69–91.
doi: 10.1146/annurev-pathmechdis-012419-032817
Park SY, Doolittle-Amieva C, Moshiri Y, Akaike T, Parvathaneni U, Bhatia S, et al. How we treat Merkel cell carcinoma: within and beyond current guidelines. Future Oncol. 2021;17(11):1363–77.
doi: 10.2217/fon-2020-1036
pubmed: 33511866
pmcid: 7983043
Baker M, Cordes L, Brownell I. Avelumab: a new standard for treating metastatic merkel cell carcinoma. Expert Rev Anticancer Ther. 2018;18(4):319–26.
doi: 10.1080/14737140.2018.1445528
pubmed: 29482384
Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, Dangelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374–85.
doi: 10.1016/S1470-2045(16)30364-3
pubmed: 27592805
pmcid: 5587154
D’Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021;9(7):e002646.
doi: 10.1136/jitc-2021-002646
pubmed: 34301810
pmcid: 8311489
Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–52.
doi: 10.1056/NEJMoa1603702
pubmed: 27093365
pmcid: 4927341
Bradford D, Demko S, Jin S, Mishra-Kalyani P, Beckles AR, Goldberg KB, et al. FDA accelerated approval of pembrolizumab for recurrent locally advanced or metastatic Merkel cell carcinoma. Oncologist. 2020;25(7):e1077–82.
doi: 10.1634/theoncologist.2020-0184
pubmed: 32272501
pmcid: 7356706
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9(4):e002478.
doi: 10.1136/jitc-2021-002478
pubmed: 33879601
pmcid: 8061836
Topalian SL, Bhatia S, Hollebecque A, Awada A, Boer JPD, Kudchadkar RR, et al. Abstract CT074: non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (nivo) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res. 2017;77(13_Supplement):CT074.
doi: 10.1158/1538-7445.AM2017-CT074
Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the checkmate 358 trial. J Clin Oncol. 2020;38(22):2476–87.
doi: 10.1200/JCO.20.00201
pubmed: 32324435
pmcid: 7392746
Grignani G, Rutkowski P, Lebbe C, Guida M, Gaudy Marqueste C, De Braud FGM, et al. Updated results from POD1UM-201: a phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Ann Oncol. 2023;34:S686.
doi: 10.1016/j.annonc.2023.09.2280
Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol. 2013;14(2):249–63.
doi: 10.1007/s11864-013-0225-9
pubmed: 23436166
pmcid: 3651762
Steuten L, Garmo V, Phatak H, Sullivan SD, Nghiem P, Ramsey SD. Treatment patterns, overall survival, and total healthcare costs of advanced Merkel cell carcinoma in the USA. Appl Health Econ Health Policy. 2019;17(5):733–40.
doi: 10.1007/s40258-019-00492-5
pubmed: 31250217
pmcid: 6748883
Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294–301.
doi: 10.1002/cam4.815
pubmed: 27431483
pmcid: 5055152
Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699–710.
doi: 10.2217/fon-2017-0187
pubmed: 28605939
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693–702.
doi: 10.1200/JCO.18.01896
pubmed: 30726175
pmcid: 6424137
U.S. Food & Drug Administration. FDA grants accelerated approval toretifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cellcarcinoma. Silver Spring, MD: U.S. Food & Drug Administration; 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel .
Lohray R, Verma KK, Wang LL, Haynes D, Lewis DJ. Avelumab for advanced Merkel cell carcinoma: global real-world data on patient response and survival. Pragmat Obs Res. 2023;14:149–54.
pubmed: 38021416
pmcid: 10658947
Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022;10(8):e004904.
doi: 10.1136/jitc-2022-004904
pubmed: 35981787
pmcid: 9394192
Bhanegaonkar A, Liu FX, Boyd M, Fulcher N, Kim R, Krulewicz S, et al. Real-world clinical outcomes in patients with locally advanced or metastatic Merkel cell carcinoma treated in U.S. oncology clinical practices: results from SPEAR-Merkel. Oncologist. 2021;26(9):e1633–43.
doi: 10.1002/onco.13845
pubmed: 34101298
pmcid: 8417847
Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021;144:182–91.
doi: 10.1016/j.ejca.2020.11.010
pubmed: 33360855